Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Stuart J Pocock

Showing results (201-210 of 349) with videos related to

Pageof 35
Sort By:
European Journal of Heart Failure|July 7, 2022
Biomarker-driven prognostic models in chronic heart failure with preserved ejection fraction: the EMPEROR-Preserved trialStuart J Pocock, João Pedro Ferreira, Milton Packer, et al.
European Journal of Heart Failure|December 1, 2023
Effects of empagliflozin on collagen biomarkers in patients with heart failure: Findings from the EMPEROR trialsJoão Pedro Ferreira, Javed Butler, Stefan D Anker, et al.
JACC. Heart Failure|June 23, 2014
Effect of rosuvastatin on repeat heart failure hospitalizations: the CORONA Trial (Controlled Rosuvastatin Multinational Trial in Heart Failure)Jennifer K Rogers, Pardeep S Jhund, Ana-Cristina Perez, et al.
Journal of the American College of Cardiology|May 7, 2025
Effect of Empagliflozin on the Mechanisms Driving Erythropoiesis and Iron Mobilization in Patients With Heart Failure: The EMPEROR ProgramJoão Pedro Ferreira, Stefan D Anker, Javed Butler, et al.
European Journal of Heart Failure|April 25, 2017
Effects of ferric carboxymaltose on hospitalisations and mortality rates in iron-deficient heart failure patients: an individual patient data meta-analysisStefan D Anker, Bridget-Anne Kirwan, Dirk J van Veldhuisen, et al.
European Journal of Heart Failure|June 6, 2023
Liver tests, cardiovascular outcomes and effects of empagliflozin in patients with heart failure and preserved ejection fraction: The EMPEROR-Preserved trialMichael Böhm, Javed Butler, Marcin Krawczyk, et al.
Journal of the American College of Cardiology|September 24, 2021
Empagliflozin Improves Cardiovascular and Renal Outcomes in Heart Failure Irrespective of Systolic Blood PressureMichael Böhm, Stefan D Anker, Javed Butler, et al.
Open Heart|December 16, 2021
Atrial fibrillation and clinical outcomes 1 to 3 years after myocardial infarctionAnthony P Carnicelli, Ruth Owen, Stuart J Pocock, et al.
Clinical Cardiology|December 17, 2017
Rationale and design of the long-Term rIsk, clinical manaGement, and healthcare Resource utilization of stable coronary artery dISease in post-myocardial infarction patients (TIGRIS) studyDirk Westermann, Shaun G Goodman, José C Nicolau, et al.
Journal of the American College of Cardiology|June 30, 2022
Empagliflozin Improves Outcomes in Patients With Heart Failure and Preserved Ejection Fraction Irrespective of AgeMichael Böhm, Javed Butler, Gerasimos Filippatos, et al.
Pageof 35

Showing results (201-210 of 349) with videos related to

Sort By:
Pageof 35
European Journal of Heart Failure|July 7, 2022
Biomarker-driven prognostic models in chronic heart failure with preserved ejection fraction: the EMPEROR-Preserved trialStuart J Pocock, João Pedro Ferreira, Milton Packer, et al.
European Journal of Heart Failure|December 1, 2023
Effects of empagliflozin on collagen biomarkers in patients with heart failure: Findings from the EMPEROR trialsJoão Pedro Ferreira, Javed Butler, Stefan D Anker, et al.
JACC. Heart Failure|June 23, 2014
Effect of rosuvastatin on repeat heart failure hospitalizations: the CORONA Trial (Controlled Rosuvastatin Multinational Trial in Heart Failure)Jennifer K Rogers, Pardeep S Jhund, Ana-Cristina Perez, et al.
Journal of the American College of Cardiology|May 7, 2025
Effect of Empagliflozin on the Mechanisms Driving Erythropoiesis and Iron Mobilization in Patients With Heart Failure: The EMPEROR ProgramJoão Pedro Ferreira, Stefan D Anker, Javed Butler, et al.
European Journal of Heart Failure|April 25, 2017
Effects of ferric carboxymaltose on hospitalisations and mortality rates in iron-deficient heart failure patients: an individual patient data meta-analysisStefan D Anker, Bridget-Anne Kirwan, Dirk J van Veldhuisen, et al.
European Journal of Heart Failure|June 6, 2023
Liver tests, cardiovascular outcomes and effects of empagliflozin in patients with heart failure and preserved ejection fraction: The EMPEROR-Preserved trialMichael Böhm, Javed Butler, Marcin Krawczyk, et al.
Journal of the American College of Cardiology|September 24, 2021
Empagliflozin Improves Cardiovascular and Renal Outcomes in Heart Failure Irrespective of Systolic Blood PressureMichael Böhm, Stefan D Anker, Javed Butler, et al.
Open Heart|December 16, 2021
Atrial fibrillation and clinical outcomes 1 to 3 years after myocardial infarctionAnthony P Carnicelli, Ruth Owen, Stuart J Pocock, et al.
Clinical Cardiology|December 17, 2017
Rationale and design of the long-Term rIsk, clinical manaGement, and healthcare Resource utilization of stable coronary artery dISease in post-myocardial infarction patients (TIGRIS) studyDirk Westermann, Shaun G Goodman, José C Nicolau, et al.
Journal of the American College of Cardiology|June 30, 2022
Empagliflozin Improves Outcomes in Patients With Heart Failure and Preserved Ejection Fraction Irrespective of AgeMichael Böhm, Javed Butler, Gerasimos Filippatos, et al.
Pageof 35